Roeland, Eric J. http://orcid.org/0000-0002-3674-3573
Phull, H.
Hagmann, C.
Sera, C.
Dullea, A. D.
El-Jawahri, A.
Nelson, S.
Gallivan, A.
Ma, J. D.
Nipp, R. D.
Baracos, V. E.
Funding for this research was provided by:
Alliance Cancer Control Program Junior Faculty Award (UG1CA189823)
UC San Diego Clinical Translational Research Institute KL2 Career Development Award (KL2TR001444)
Cambia Health Foundation Sojourns Scholar Award
Article History
Received: 8 June 2020
Accepted: 28 August 2020
First Online: 29 September 2020
Compliance with ethical standards
:
: Dr. Roeland is a consultant for the BASF, Napo Pharmaceuticals, Imuneering, Asahi Kasei Pharma, Prime Oncology, and American Imaging Management. He also has served on advisory boards for Heron Therapeutics and Vector Oncology. He also serves on the Data Safety Monitoring Board for the Galera Therapeutics, Oragenics Inc., and Enzychem Lifesciences.